Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology

Experimental Lung Research

Volumn 31, Issue 6, 2005, Pages 599-621

  Chakrabarti, Subhadeep ^a   Patel, Kamala D ^a  

^a NONE

Author keywords

Asthma; COPD; Gelatinase; Lung; Neutrophil; Remodeling

Indexed keywords

AGGRECAN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; BATIMASTAT; BREVICAN; COLLAGEN; DECORIN; ELASTIN; ENDOTHELIN 1; FIBRONECTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATIN; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; KALININ; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 3; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNINDEXED DRUG; VITRONECTIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; BREATHING; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; LUNG BLOOD VESSEL; LUNG DISEASE; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG INFECTION; LUNG LAVAGE; LUNG TUMOR; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; HUMANS; LUNG; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 22044450897     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/019021490944232     Document Type: Review

References (127)

1. Nagese H, Woessner JF, Jr.: Matrix metalloproteinses. J Biol Chem. 1999;274:21491.
2. Vu TH: Don't mess with the matrix. Nat Genet. 2001;28:202.
3. Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001;22:571.
4. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J: Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851.
5. Proost P, Van Damme J, Opdenakker G: Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun. 1993;192:1175.
6. Shipley JM, Doyle GA, Fliszer CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, Senior RM: The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem. 1996;271:4335.
7. Frisch SM, Morisaki JH: Positive and negative transcriptional elements of the human type IV collagenase gene. Mol Cell Biol. 1990;10:6524.
8. Devarajan P, Johnston JJ, Ginsberg SS, Van Wart HE, Berliner N: Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells. J Biol Chem. 1992;267:25228.
9. Schwingshackl A, Duszyk M, Brown N, Moqbel R: Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. Allergy Clin Immunol. 1999;104:983.
10. Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RA: Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int. 2001;25:411.
11. Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K: Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 1991;266:16485.
12. Templeton NS, Stetler-Stevenson WG: Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res. 1991;51:6190.
13. Zucker S, Hymowitz M, Conner C, DeClerck Y, Cao J: TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. Exp Cell Res. 2004;293:164.
14. Nguyen M, Arkell J, Jackson CJ: Activated protein C directly activates human endothelial gelatinase A. J Biol Chem. 2000;275:9095.
15. Nguyen M, Arkell J, Jackson CJ: Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MTI matrix metalloproteinase. Lab Invest. 1999;79:467.
16. Ogata Y, Enghild JJ, Nagase H: Matrix metalloprioteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:3581.
17. Maeda H, Okamoto T, Akaike T: Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals. Biol Chem. 1998;379:193.
18. Crocker SJ, Pagenstecher A, Campbell IL: The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res. 2004;75:1.
19. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992;267:4583.
20. Atkinson JJ, Senior RM: Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28:12.
21. Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z: Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol. 2002;128:197.
22. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z, Delaisse JM: Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol. 2000;151:879.
23. Nguyen M, Arkell J, Jackson CJ: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001;33:960.
24. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST: Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001;20:185.
25. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737.
26. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman, HK: Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol. 1995;165:107.
27. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchel MA: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol. 1994;162:499.
28. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411.
29. Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C, Harf A: Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol. 1996;14:288.
30. Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, Kaplan H, Birembaut P, Tournier JM: Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol. 1999;146:517.
31. Vermaelen KY, Cataldo D, Tournoy K, Maes T, Dhulst A, Louis R, Foidart JM, Noel A, Pauwels R: Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a crucial step in a mouse model of asthma. J Immunol. 2003;171:1016.
32. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagnists with anti-inflammatory properties in vivo. Blood. 2002;100:1160.
33. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G: Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem. 2003;270:3739.
34. Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G: Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun. 2003;310:889.
35. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Mover M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME: The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry. 2002;41:9462.
36. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163.
37. Schonbeck U, Mach F, Libby P: Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340.
38. Tonnel AB, Gosset P, Tillie-Leblond I: Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus. Int Arch Allergy Immunol. 2001;124:267.
39. Lemjabbar H, Cosset P, Lamblin C, Tillie I, Hartmann D, Wallaert B, Tonnel AB, Lafuma C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med. 1999;159:1298.
40. Kim JH, Lee SY, Bak SM, Suh IB, Shin C, Shim JJ, In KH, Kang KH, Yoo SH: Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia. Am J Physiol Lung Cell Mol Physiol. 2004;287:L127.
41. Hoshino M, Takahashi M, Takai Y, Sim J: Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol. 1999;104:356.
42. Maisi P, Prikk K, Sepper R, Pirila E, Salo T, Hietanen J, Sorsa T: Soluble membrane-type I matrix metalloproteinase (MTI-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. Apmis. 2002;110:771.
43. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F: Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol. 1997;17:583.
44. Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD: Wallace JL, Befus AD, Moqbel R: Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol. 2000;106:537.
45. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, Mautino G, D'Accardi P, Bousquet J, Bonsignore G: Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1998;158:1945.
46. Kelly EA, Jarjour NN: Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med. 2003;9:28.
47. Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D: Lung inflammation and epithelial changes in a murine model of atopic asthma. Am J Respir Cell Mol Biol. 1996;14:425.
48. Lee KS, Jin SM, Kim SS, Lee YC: Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol. 2004;113:902.
49. Kumagai K, Ohno I, Okada S; Ohkawara Y, Suzuki K, Shinya T, Nagase H, Iwata K, Shirato K: Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol. 1999;162:4212.
50. Barnes PJ: New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113.
51. Hogg JC, Senior RM: Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax. 2002;57:830.
52. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602.
53. Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venges P, Xu S, Kawakami Y: Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999;159:1985.
54. McCrea KA, Ensor JE, Nall K, Bleecker ER, Hasday JD: Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med. 1994;150:696.
55. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96:2673.
56. Beatty K, Bieth J, Travis J: Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem. 1980;255:3931.
57. Ohlsson K: Alpha1-antitrypsin and alpha2-macroglobulin. Interactions with human neutrophil collagenase and elastase. Ann N Y Acad Sci. 1975;256:409.
58. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 1998;78:1077.
59. Lomas DA, Parfrey H: Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax. 2004;59:529.
60. Sandford AJ, Weir TD, Pare PD: Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997;10:1380.
61. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W, De Boer WI: 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:490.
62. MacNee W, Rahman I: Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med. 2001;7:55.
63. Lanone S, Zheng T, Zhu Z, Liu W, Lee CG, Ma B, Chen Q, Homer RJ, Wang J, Rabach LA, Rabach ME, Shipley JM, Shapiro SD, Senior RM, Elias JA: Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest. 2002;110:463.
64. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ, Jr, Chapman HA, Shapiro SD, Elias JA: Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106:1081.
65. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A: TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol. 2000;279:L562.
66. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A: Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24:591.
67. Fukada Y, Ishizaki M, Kudoh S, Kitaichi M, Yamanaka N: Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest. 1998;78:687.
68. Lemjabbar H, Gosset P, Lechapt-Zalcman E, Franco-Monotoya ML, Wallaert B, Harf A, Lafuma O: Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol. 1999;20:903.
69. Perez-Ramos J, de Lourdes Segura-Valdez M, Vanda B, Selman M, Pardo A: Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am J Respir Crit Care Med. 1999;160:1274.
70. Madtes DK, Elston AL, Kaback LA, Clark JG: Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001;24:599.
71. Corbel M, Theret N, Caulet-Maugendre S, Germain N, Lagente V, Clement B, Boichot E: Repeated endotoxin exposure induces interstitial fibrosis associated with enhanced gelatinase (MMP-2 and MMP-9) activity. Inflamm Res. 2001;50:129.
72. Corbel M, Lanchou J, Germain N, Malledant Y, Boichot E, Lagente V: Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. Eur J Pharmacol. 2001;426:113.
73. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM: Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol. 2000;157:525.
74. Pallister I, Dent C, Topley N: Increased neutrophil migratory activity after major trauma: a factor in the ethiology of acute respiratory distress syndrome? Crit Care Med. 2002;30:1717.
75. Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, Theret N, Clement B, Lagente V, Malledant Y: Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med. 2003;31:536.
76. Torii K, Iida K, Miyazaki Y, Saga S, Kondoh Y, Taniguchi H, Taki F, Takagi K, Matsuyama M, Suzuki R: Higher concentrations of matrix metalloproteinases in bronchialveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:43.
77. Eichler W, Bechtel JF, Schumacher J, Wermelt JA, Klotz KF, Bartels C: A rise of MMP-2 and MMP-9 in bronchoalveolar lavage fluid is associated with acute lung injury after cardiopulmonary bypass in a swine model. Perfusion. 2003;18:107.
78. Warner RL, Beltra L, Younkin EM, Lewis CS, Weiss SJ, Varani J, Johnson KJ: Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol Biol. 2001;24:537.
79. Keck T, Balcom JHT, Fernandez-del Castillo C, Antoniu BA, Warshaw AL: Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology. 2002;122:188.
80. Carney DE, Lutz CJ, Picone AL, Gatto LA, Ramamurthy NS, Golub LM, Simon SR, Searles B, Paskanik A, Snyder K, Finck C, Schiller HJ, Niemen GF: Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary by pass. Circulation. 1999;100:400.
81. Steimberg J, Halter J, Schiller HJ, Dasilva M, Landas S, Gatto LA, Maisi P, Sorsa T, Rajamaki M, Lee HM, Nieman GF: Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res. 2003;111:185.
82. Qu J, Rong Z, He L, Pan J, Chen X: Relationship between the burden of pneumocystis carinii, the inflammatory reaction and lung injury in Pneumocystis carinii pneumonia. Chin Med J (Engl). 2000;113:1071.
83. Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J: Occurrence of matrix metalloproteinase and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb). 2001;81:203.
84. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z: Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis. 2002;6:713.
85. Ragno S, Romano M, Howell S, Pappin DJ, Jenner PJ, Colston MJ: Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach. Immunology. 2001;104:99.
86. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom W: Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax. 1996;51:306.
87. Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J: Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med. 2003;167:593.
88. van Kempen LC, Coussens LM: MMP9 potentiates pulmonary metastasis formation. Cancer Cell. 2002;2:251.
89. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinen M, Wittekind C: Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells and squamous cell carcinomas of the lung. Tumour Biol. 2002;23:179.
90. Reichenberger F, Eickelberg O, Wyser C, Perruchoud AP, Roth M, Tamm M: Distinct endobronchial expression of matrix-metalloproteinases (MMP) and their endogenous inhibitors in lung cancer. Swiss Med Wkly. 2001;131:273.
91. Iijima T, Minami Y, Nakamura N, Onizuka M, Morishita Y, Inadome Y, Noguchi M: MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: analysis of MMP-2 and MMP-9 with gelatin zymography. Pathol Int. 2004;54:295.
92. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, Meek AG, Zucker S: Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1161.
93. Sato T, Iwai M, Sakai T, Sato H, Seiki M, Mori Y, Ito A: Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. Br J Cancer. 1999;80:1137.
94. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler-Stevenson WG, Lippman ME, Thompson EW: Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004;64:652.
95. Murray D, Morrin M, McDonnell S: Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res. 2004;24:489.
96. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2:289.
97. Parks WC, Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res. 2001;2:10.
98. Corry DB, Rishi K, Kanellis J, Kiss A, Song Lz LZ, Xu J, Feng L, Werb Z, Kheradmand F: Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol. 2002;3:347.
99. Esparza J, Kruse M, Lee J, Michaud M, Madri A: MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity FASEB J. 2004;18:1682.
100. Dubois B, Arnold B, Opdenakker G: Gelatinase B deficiency impairs reproduction. J Clin Invest. 2000;106:627.
101. Betsuyaku T, Shipley JM, Liu Z, Senior RM: Neutrophil emigration in lungs, peritoneum and skin does not require gelatinase B. Am J Respir Cell Mol Biol. 1999;20:1303.
102. McMillan SJ, Kearley J, Campbell JD, Zhu XW, Larbi KY, Shipley JM, Senior RM, Nourshargh S, Lloyd CM. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol. 2004;172:2586.
103. Corry DB, Kiss A, Song LZ, Song L, Xu J, Lee SH, Werb Z, Kheradmand F: overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 2004;18:995.
104. Hidalgo M, Eckhardt G: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178.
105. Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, Scanziani E, Casazza AM, Taraboletti G, Giavazzi R: BAY 12-9566, a novel inhibitor of matrix metalloproteinases with anti-angiogenic activity. Clin Cancer Res. 1999;5:3603.
106. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T: In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone. 1998;22:33.
107. Belvisi MG, Bottomley KM: The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res. 2003;52:95.
108. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150.
109. Zucker S, Cao J, Chen WT: Critical appraisal of the use of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642.
110. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12.
111. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H: A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004;10:1963.
112. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R: Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001;12:389.
113. Heath KI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB: Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001;48:269.
114. Liacini A, Sylvester J, Li WQ, Zafarullah M: Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expressions in articular chonodrocytes. Matrix Biol. 2002;21:251.
115. Shin M, Yan C, Boyd D: An inhibitor of c-Jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002;1589:311.
116. Gerrits CM, Herings RM, Leufkenes HG, Lammers JW: N-acetylcysteine reduces the risk of rehospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21:795.
117. Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Aston K, Riley DP, Salvemini D: Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. Br J Pharmacol. 2001;132:19.
118. Lauhio A, Salo T, Ding Y, Konttinen YT, Nordstrom D, Tschesche H, Lahdevirta J, Golun LM, Sorsa T: In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination theraphy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol. 1994;98:21.
119. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW: Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336.
120. Mast AE, Enghild JJ, Nagase H, Suzuki K, Pizzo SV, Salvesen G: Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-anticgymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kD gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem. 1991;266:15810.
121. Arbelaez LF, Bergmann U, Tuuttila A, Shanbhag VP, Stigbrand T: Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin. Arch Biochem Biophys. 1997;347:62.
122. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clar-Lewis I, Overall GM: Matrix metalloproteinases activity inactivates the CXN chemokine stromall cell-derived factor-1. J Biol Chem. 2001;276:43503.
123. Gearing AJ, Beckett P, Christodoulov M, Churchill M, Clements J, Davidson AH, Dummond AH, Galloway WA, Gilbert R, Gordon JL, et al: Processing of tumour necrosis factor-alpha precursor by metalloproteinase. Nature. 1994;370:555.
124. Fernandez-Partron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906.
125. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z: The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000;102:647.
126. Sheu BC, Hsu SM, Ho HN, Lieu HC, Huang SC, Liu RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61:237.
127. Allport JR, Lim YC, Shipley JM, Senior RM, Shapiro SD, Matsuyoshi N, Vestweber D, Luscinskas FM: Neutrophils from MMP-9- or neutrophil elastase-deficient mice show no defect in transendothelial migration under flow in vitro. J Leukoc Biol. 2002;71:821.